Search

Your search keyword '"Curti B"' showing total 308 results
Start Over Author "Curti B"
308 results on '"Curti B"'

2. 785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)

Author

Diab, A., primary, Gogas, H.J., additional, Sandhu, S.K., additional, Long, G.V., additional, Ascierto, P.A., additional, Larkin, J., additional, Sznol, M., additional, Franke, F.A., additional, Ciuleanu, T-E., additional, Muñoz Couselo, E., additional, Perfetti, A., additional, Lebbe, C., additional, Meier, F., additional, Curti, B., additional, Rojas, C., additional, Yang, H., additional, Zhou, M., additional, Ravimohan, S., additional, Tagliaferri, M.A., additional, and Khushanlani, N., additional

Published
2022
Full Text
View/download PDF

5. Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update

Author

Sarnaik, A. (Amod), Khushalani, N. (Nikhil), Chesney, J. (Jason), Kluger, H. (Harriet), Curti, B. (Brendan), Lewis, K. (Karl), Medina, T. (Theresa), Thomas, S. (Sajeve), Pavlick, A. (Anna), Whitman, E. (Eric), Martin-Algarra, S. (Salvador), Corrie, P. (Pippa), Hamid, O. (Omid), Lutzky, J. (Jose), Olah, J. (Judit), Weber, J.S. (Jeffrey S.), Larkin, J. (James), Shi, W. (Wen), DiTrapani, K. (Kelly), Qin, H. (Harry), Mirgoli, M. (Mariam), Wu, R. (Renee), Takamura, T. (Toshimi), Fardis, M. (Maria), and Kirkwood, J.M. (John M.)

Subjects
Inhibitors, Treatment options, Advanced melanoma, Cell therapy
Abstract

Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies such as BRAF/MEK inhibitors (if BRAF-V600E mutated). Adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) has shown antitumor efficacy with durable responses in heavily pretreated melanoma patients. Safety and efficacy of lifileucel, a centrally manufactured cryopreserved autologous TIL therapy assessed by both investigator and an independent review committee (IRC), are presented.

Published
2020

10. Forum on Charlotte Cotton, 'Photography is magic'

Author

O. Meo, A.-K. Rastenberger, D. Curti, B. Burbridge, Ed. By C. Spenuso, With C. Cotton

Subjects
lcsh:BH1-301, lcsh:B, lcsh:Philosophy. Psychology. Religion, lcsh:Aesthetics
Abstract

__, Lebenswelt. Aesthetics and philosophy of experience., N. 9 (2016)

Published
2016

11. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.

Author

Fishman, M., Dutcher, J. P., Clark, J. I., Alva, A., Miletello, G. P., Curti, B., Agarwal, Neeraj, Hauke, R., Mahoney, K. M., Moon, H., Treisman, J., Tykodi, S. S., Daniels, G., Morse, M. A., Wong, M. K. K., Kaufman, H., Gregory, N., and McDermott, D. F.

Subjects
RENAL cancer, OVERALL survival, INTERLEUKIN-2, CANCER cells, RENAL cell carcinoma
Abstract

Background: Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkpoint inhibitory immunotherapy and tyrosine kinase inhibitor therapy, but have not been applied extensively to patients receiving high dose interleukin-2 (HD IL-2) immunotherapy. Methods: Survival of 810 mRCC patients treated from 2006 to 2017 with high dose IL-2 (aldesleukin) and enrolled in the PROCLAIMSM registry data base was assessed utilizing the International Metastatic RCC Database Consortium (IMDC) risk criteria. Median follow-up is 23.4 months (mo.) (range 0.2-124 mo.). Subgroup evaluations were performed by separating patients by prior or no prior therapy, IL-2 alone, or therapy subsequent to IL-2. Some patients were in two groups. We will focus on the 356 patients who received IL-2 alone, and evaluate outcome by risk factor categories. Results: Among the 810 patients, 721 were treatment-naïve (89%) and 59% were intermediate risk. Overall, of the 249 patients with favorable risk, the median overall survival (OS) is 63.3 mo. and the 2-year OS is 77.6%. Of 480 patients with intermediate risk, median OS is 42.4 mo., 2-year OS 68.2%, and of 81 patients with poor risk, median OS 14 mo., 2-year OS 40.4%. Among those who received IL-2 alone (356 patients), median OS is 64.5, 57.6, and 14months for favorable, intermediate and poor risk categories respectively. Two year survival among those treated only with HD IL-2 is 73.4, 63.7 and 39.8%, for favorable, intermediate and poor risk categories respectively. Conclusions: Among mRCC patients treated with HD IL-2, all risk groups have median and 2-year survival consistent with recent reports of checkpoint or targeted therapies for mRCC. Favorable and intermediate risk (by IMDC) patients treated with HD IL-2 have longer OS compared with poor risk patients, with most durable OS observed in favorable risk patients. Favorable risk patients treated with HD IL-2 alone have a 2-year OS of 74%. These data continue to support a recommendation for HD IL-2 for patients with mRCC who meet eligibility criteria. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

13. P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

Author

Papadimitrakopoulou, V., primary, Tannir, N., additional, Bernatchez, C., additional, Haymaker, C., additional, Bentebibel, S., additional, Curti, B., additional, Wong, M., additional, Gergel, I., additional, Tagliaferri, M., additional, Zalevsky, J., additional, Hoch, U., additional, Aung, S., additional, Imperiale, M., additional, Cho, D., additional, Tykodi, S., additional, Puzanov, I., additional, Kluger, H., additional, Hurwitz, M., additional, Hwu, P., additional, Sznol, M., additional, and Diab, A., additional

Published
2017
Full Text
View/download PDF

17. FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the 'Melanoma Research: A bridge from Naples to the World. Napoli, December 5 th-6 th2011'

Author

Ascierto, P.A. Grimaldi, A.M. Curti, B. Faries, M.B. Ferrone, S. Flaherty, K. Fox, B.A. Gajewski, T.F. Gershenwald, J.E. Gogas, H. Grossmann, K. Hauschild, A. Hodi, F.S. Kefford, R. Kirkwood, J.M. Leachmann, S. Maio, M. Marais, R. Palmieri, G. Morton, D.L. Ribas, A. Stroncek, D.F. Stewart, R. Wang, E. Mozzillo, N. Marincola, F.M.

Abstract

After more than 30 years, landmark progress has been made in the treatment of cancer, and melanoma in particular, with the success of new molecules such as ipilimumab, vemurafenib and active specific immunization.After the first congress in December 2010, the second edition of " Melanoma Research: a bridge from Naples to the World" meeting, organized by Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (NIH, Bethesda, USA), and Nicola Mozzillo (INT, Naples, Italy) took place in Naples, on 5-6 December 2011. We have identified four new topics of discussion: Innovative Approaches in Prevention, Diagnosis and Surgical Treatment, New Pathways and Targets in Melanoma: An Update about Immunotherapy, and Combination Strategies.This international congress gathered more than 30 international faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive atmosphere which stimulated discussion of new approaches and strategies in the field of melanoma. © 2012 Ascierto et al.; licensee BioMed Central Ltd.

Published
2012

18. 3336 Phase II CALM extension study: Enhanced immune-cell infiltration within the tumour micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21

Author

Andtbacka, R.H.I., primary, Curti, B., additional, Hallmeyer, S., additional, Feng, Z., additional, Paustian, C., additional, Bifulco, C., additional, Fox, B., additional, Grose, M., additional, Davies, B., additional, Karpathy, R., additional, and Shafren, D., additional

Published
2015
Full Text
View/download PDF

19. 3335 Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses

Author

Andtbacka, R.H.I., primary, Curti, B., additional, Kaufman, H.L., additional, Daniels, G.A., additional, Nemunaitis, J.J., additional, Spitler, L.E., additional, Hallmeyer, S., additional, Lutzky, J., additional, Schultz, S., additional, Whitman, E.D., additional, Zhou, K., additional, Karpathy, R., additional, Weisberg, J.I., additional, and Shafren, D., additional

Published
2015
Full Text
View/download PDF

32. Molecular dynamics simulation of the interaction between the complex iron-sulfur flavoprotein glutamate synthase and its substrates

Author

Coiro V and M. Di Nola A. Vanoni MA. Aschi M. Coda A. Curti B. Roccatano D.

Abstract

Glutamate synthase (GltS) is a complex iron-sulfur flavoprotein that catalyzes the reductive transfer of L-glutamine amide group to the C2 carbon of 2-oxoglutarate yielding two molecules of L-glutamate. Molecular dynamics calculations in explicit solvent were carried out to gain insight into the conformational flexibility of GltS and into the role played by the enzyme substrates in regulating the catalytic cycle. We have modelled the free (unliganded) form of Azospirillum brasilense GltS alpha subunit and the structure of the reduced enzyme in complex with the L-glutamine and 2-oxoglutarate substrates starting from the crystallographically determined coordinates of the GltS alpha subunit in complex with L-methionine sulphone and 2-oxoglutarate. The present 4-ns molecular dynamics calculations reveal that the GltS glutaminase site may exist in a catalytically inactive conformation unable to bind glutamine, and in a catalytically competent conformation, which is stabilized by the glutamine substrate. Substrates binding also induce (1) closure of the loop formed by residues 263-271 with partial shielding of the glutaminase site from solvent, and (2) widening of the ammonia tunnel entrance at the glutaminase end to allow for ammonia diffusion toward the synthase site. The Q-loop of glutamate synthase, which acts as an active site lid in other amidotransferases, seems to maintain an open conformation. Finally, binding of L-methionine sulfone, a glutamine analog that mimics the tetrahedral transient species occurring during its hydrolysis, causes a coordinated rigid-body motion of seaments of the glutaminase domain that results in the inactive conformation observed in the crystal structure of GltS alpha subunit.

Published
2004

33. Calm Study: Secondary Endpoints of a Phase Ii Study of a Novel Oncolytic Immunotherapeutic Agent, Coxsackievirus A21, Delivered Intratumorally in Patients with Advanced Malignant Melanoma

Author

Andtbacka, R.H., primary, Curti, B., additional, Kaufman, H., additional, Daniels, G.A., additional, Nemunaitis, J.J., additional, Spitler, L.E., additional, Hallmeyer, S., additional, Lutzky, J., additional, Schultz, S., additional, Whitman, E.D., additional, Zhou, K., additional, Weisberg, J.I., additional, and Shafren, D., additional

Published
2014
Full Text
View/download PDF

34. Immunomodulatory Activity of Nivolumab in Previously Treated and Untreated Metastatic Renal Cell Carcinoma (Mrcc): Biomarker-Based Results from a Randomized Clinical Trial

Author

Choueiri, T., primary, Fishman, M.N., additional, Escudier, B., additional, Kim, J.J., additional, Kluger, H., additional, Stadler, W.M., additional, Perez-Garcia, J.L., additional, McNeel, D., additional, Curti, B., additional, Harrison, M.R., additional, Plimack, E.R., additional, Appleman, L., additional, Fong, L., additional, Drake, C.G., additional, Cohen, L., additional, Srivastava, S., additional, Jure-Kunkel, M., additional, Hong, Q., additional, Kurland, J., additional, and Sznol, M., additional

Published
2014
Full Text
View/download PDF

39. FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the 'Melanoma Research: A bridge from Naples to the World. Napoli, December 5 th-6 th2011'

Author

Ascierto, PA, Grimaldi, AM, Curti, B, Faries, MB, Ferrone, S, Flaherty, K, Fox, BA, Gajewski, TF, Gershenwald, JE, Gogas, H, Grossmann, K, Hauschild, A, Hodi, FS, Kefford, R, Kirkwood, JM, Leachmann, S, Maio, M, Marais, R, Palmieri, G, Morton, DL, Ribas, A, Stroncek, DF, Stewart, R, Wang, E, Mozzillo, N, Marincola, FM, Ascierto, PA, Grimaldi, AM, Curti, B, Faries, MB, Ferrone, S, Flaherty, K, Fox, BA, Gajewski, TF, Gershenwald, JE, Gogas, H, Grossmann, K, Hauschild, A, Hodi, FS, Kefford, R, Kirkwood, JM, Leachmann, S, Maio, M, Marais, R, Palmieri, G, Morton, DL, Ribas, A, Stroncek, DF, Stewart, R, Wang, E, Mozzillo, N, and Marincola, FM

Abstract

After more than 30 years, landmark progress has been made in the treatment of cancer, and melanoma in particular, with the success of new molecules such as ipilimumab, vemurafenib and active specific immunization.After the first congress in December 2010, the second edition of " Melanoma Research: a bridge from Naples to the World" meeting, organized by Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (NIH, Bethesda, USA), and Nicola Mozzillo (INT, Naples, Italy) took place in Naples, on 5-6 December 2011. We have identified four new topics of discussion: Innovative Approaches in Prevention, Diagnosis and Surgical Treatment, New Pathways and Targets in Melanoma: An Update about Immunotherapy, and Combination Strategies.This international congress gathered more than 30 international faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive atmosphere which stimulated discussion of new approaches and strategies in the field of melanoma. © 2012 Ascierto et al.; licensee BioMed Central Ltd.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results